Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Current Leases (2023 - 2025)

Historic Current Leases for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $2.2 million.

  • Inhibrx Biosciences' Current Leases rose 2245.23% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 2245.23%. This contributed to the annual value of $1.6 million for FY2024, which is 2268.54% down from last year.
  • Per Inhibrx Biosciences' latest filing, its Current Leases stood at $2.2 million for Q3 2025, which was up 2245.23% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Current Leases registered a high of $2.2 million during Q3 2025, and its lowest value of $1.6 million during Q4 2024.
  • For the 3-year period, Inhibrx Biosciences' Current Leases averaged around $2.0 million, with its median value being $2.1 million (2023).
  • Its Current Leases has fluctuated over the past 5 years, first plummeted by 2268.54% in 2024, then surged by 2245.23% in 2025.
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Current Leases stood at $2.1 million in 2023, then decreased by 22.69% to $1.6 million in 2024, then skyrocketed by 40.88% to $2.2 million in 2025.
  • Its Current Leases was $2.2 million in Q3 2025, compared to $2.2 million in Q2 2025 and $2.0 million in Q1 2025.